StreetAlpha.app
Home › Stocks › ASND

Ascendis Pharma A (ASND)

Healthcare
$252.73
▼ −1.26%
LAST CLOSE · NOV 20

Ascendis Pharma develops rare disease treatments based on its TransCon technology, including YORVIPATH and SKYTROFA. It last closed at $252.73 on Nov 20, down 1.26% on the day. Over the last 12 months ASND insiders bought $777K of stock on the open market and sold $10.8M, according to SEC Form 4 filings.

AI Auto Pilots
Is ASND in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold ASND.

Key Stats

Last 12 months
Results
Revenue
EUR 720.1M
+98.0% vs a year ago
Net income
−EUR 228.0M
−31.7% margin
Gross margin
86.8%
EUR 625.2M gross profit
Operating margin
−18.9%
−EUR 136.3M operating income
Balance sheet
Cash & equivalents
EUR 616.0M
At Dec 31
Debt
EUR 720.3M
At Dec 31
Shareholder equity
−EUR 162.8M
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: EUR 7.8MEUR 7.8MFY2021FY2022: EUR 51.2MEUR 51.2MFY2022FY2023: EUR 266.7MEUR 266.7MFY2023FY2024: EUR 363.6MEUR 363.6MFY2024FY2025: EUR 720.1MEUR 720.1MFY2025

From ASND's SEC filings, latest 20-F for the period ending Dec 31, 2025 (filed Feb 11). Last 12 months adds up the four latest quarters. Figures are in EUR. Per share figures are left out because the US listing can represent a different number of shares.

Next report
—
No date on file yet
Reported EPS
—
Quarter ended Dec 2025
Year ago EPS
—
Same quarter last year
Revenue
$247.5M
+42.3% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Not enough quarters on file yet.
Revenue by quarter
Mar 2024: $95.9MMar '24Jun 2024: $36.0MJun '24Sep 2024: $57.8MSep '24Dec 2024: $173.9MDec '24Mar 2025: $101.0MMar '25Jun 2025: $158.0MJun '25Sep 2025: $213.6MSep '25Dec 2025: $247.5MDec '25Latest $247.5M
StreetAlpha's call on ASNDStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on ASND
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on ASND

Technical Analysis

ASND · as of the Nov 20 close · updated each morning
Uptrend

The stock sits between its 20 and 50 day averages. It is 5% above its 200 day average, so the longer trend is still up. Momentum is fading (RSI 49). The nearest support is the Pivot S1 at $250.64, and the nearest resistance the Pivot at $253.64.

Short trendBullish
Long trendBullish
MomentumFading
StretchNormal
VolatilityNormal, 3.1%/day
Key levels
$282.1552 week high+11.6%
$258.55Swing high (Aug 12)+2.3%
$257.6120 day average+1.9%
$255.74Pivot R1+1.2%
$253.64Pivot+0.4%
$252.73Last close
$250.64Pivot S1−0.8%
$250.04100 day average−1.1%
$248.31Swing low (Nov 4)−1.7%
$242.5850 day average−4.0%
$240.90200 day average−4.7%
$188.0852 week low−25.6%
Indicators
RSI (14)48.56Middle of its rangeNeutral
MACD6.05Below its signal lineBearish
Stochastic37.6Middle of its rangeNeutral
ADX (14)33.9Trending down
Williams %R-85.4Oversold below −80, overbought above −20Oversold
CCI (20)-35.5Oversold below −100, overbought above 100Neutral
Rate of change−1.6%Change over 10 sessionsBearish
ATR (14)$7.80Typical daily range, 3.1% of price
MA 10Below
MA 20Below
MA 50Above
MA 100Above
MA 200Above
What happened before, for ASND

What happened before

See how ASND did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow ASND usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How ASND has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2015.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for ASNDHow many large options trades hit ASND, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

Dark Pool

30D
Prints
Notional
Largest print
Loading…

ASND Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ▲223 buying vs 144 selling
  • ▲Shares held by funds +4.0%
  • ▲Funds holding +34
  • ▼Superinvestors: 1 added, 3 cut
  • ▼Put/call 0.14 to 0.15
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holding
Q3 2026This quarterLast quarterChange
Funds holding350316+10.8%
In funds' top 101613+23.1%
Held by funds–––
New / increased83 / 140296 / 7−26.4%
Reduced / sold out96 / 484 / 267−46.9%
Put/call ratio0.150.14+7.2%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See ASND institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

ASND Insider Trading

All filings →
Insider trading · 12 months
Insiders are net sellers
Bought$777K5 buys · 2 insiders
Sold$10.8M4 sales · 4 insiders
Cluster buy: 2 insiders bought $284K between May 26 and Jun 2.
2026-05 bought $263K2026-05 sold $4.6M2026-06 bought $22K2026-08 bought $493K2026-09 sold $873K2026-11 sold $5.3MDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Nov 17Anni Lotte Kirstine Sonderbjerg PedersenEVP & Chief Admin OfficerSale20,000$263.89$5.3M
Sep 8Mads BodenhoffSVP & PaoSale3,000$270.19$811K
Sep 2Lars HoltugDirectorSale236$264.13$62K
Aug 14Jean Jacques BienaimeDirectorBuy2,000$246.33$493K
Jun 2Scott Thomas SmithEVP & CFOBuy100$219.00$22K
May 29Scott Thomas SmithEVP & CFOBuy250$223.32$56K
Every insider buy and sale for ASND over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See ASND insider trades →

From SEC Form 4 filings by ASND's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ASND is in one of them and how their past ASND trades turned out.

ASND in the AI portfolios
Loading…

ASND News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered ASND in an article yet. Here's the latest on the wider market.

ASND in the news

ASND Congress Trades

All congress trades →
Trades, 12 months
0
Buys
0
Sells
0
People
0
Last filed Nov 7
Who traded ASND · since 2018
Latest 3 filings
$1K – $15KTraded Oct 5, 2018Filed Nov 7, 2018
$1K – $15KTraded Aug 6, 2018Filed Sep 29, 2018
$1K – $15KTraded Jul 12, 2018Filed Sep 29, 2018
PersonTypeAmountTradedFiledDelay
Gary PalmerR · ALSell$1K – $15KOct 5, 2018Nov 7, 201833 d
Gary PalmerR · ALBuy$1K – $15KAug 6, 2018Sep 29, 201854 d
Gary PalmerR · ALBuy$1K – $15KJul 12, 2018Sep 29, 201879 d

From official House and Senate disclosure reports, filed up to 45 days after the trade and shown in dollar ranges. Not investment advice. Use limited by 5 U.S.C. 13107. About this data

About Ascendis Pharma A

Ascendis Pharma is a biopharmaceutical company based in Hellerup, Denmark. It develops medicines built on its TransCon technology, with a focus on rare endocrine conditions. Its approved products are YORVIPATH, for adults with hypoparathyroidism, and SKYTROFA, for people with growth hormone deficiency. The company also has product candidates in development for other growth disorders and in oncology, and it works with partners in Japan and China. Its customers are patients and the healthcare providers who prescribe its treatments.

Headquarters
Hellerup
Founded
2007